FDA Regulation of Dietary Supplements and Requirements Regarding Adverse Event Reporting

被引:36
|
作者
Frankos, V. H. [1 ]
Street, D. A. [2 ]
O'Neill, R. K. [3 ]
机构
[1] US FDA, Div Dietary Supplement Programs, College Pk, MD USA
[2] US FDA, Emergency Response & Surveillance Branch, College Pk, MD USA
[3] US FDA, Div Publ Hlth & Biostat, College Pk, MD USA
关键词
D O I
10.1038/clpt.2009.263
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In 1994, the Dietary Supplement Health and Education Act (DSHEA) amended the Federal Food, Drug, and Cosmetic Act (FDC Act) to set up a distinct regulatory framework for what we now call dietary supplements. The DSHEA was passed with the intent of striking a balance between providing consumers access to safe dietary supplements to help maintain or improve their health and giving the US Food and Drug Administration (FDA) authority to regulate and take action against manufacturers of supplements or supplement ingredients that present safety problems, are presented with false or misleading claims, or are adulterated or misbranded. This article will present FDA's recent experience in collecting and evaluating dietary supplement adverse event data for the purpose of assuring the public that the dietary supplements they purchase are safe.
引用
下载
收藏
页码:239 / 244
页数:6
相关论文
共 50 条
  • [21] Reporting associations between dietary supplements and adverse events - Reply
    Gange, Christopher A.
    Madias, Christopher
    Weintraub, Andrew R.
    Estes, N. A. Mark, III
    Felix-Getzik, Erika M.
    MAYO CLINIC PROCEEDINGS, 2006, 81 (12) : 1636 - 1637
  • [22] Adverse Event Reporting Patterns of Newly Approved Drugs in the USA in 2006: An Analysis of FDA Adverse Event Reporting System Data
    Pankdeep Chhabra
    Xing Chen
    Sheila R. Weiss
    Drug Safety, 2013, 36 : 1117 - 1123
  • [23] Adverse Event Reporting Patterns of Newly Approved Drugs in the USA in 2006: An Analysis of FDA Adverse Event Reporting System Data
    Chhabra, Pankdeep
    Chen, Xing
    Weiss, Sheila R.
    DRUG SAFETY, 2013, 36 (11) : 1117 - 1123
  • [24] Adverse event profile of CGRP monoclonal antibodies: findings from the FDA adverse event reporting database
    Wang, Qi
    Liu, Jingfang
    Sun, Hao
    Dong, Yongfei
    Tan, Weiliang
    Tang, Zaixiang
    Jiang, Yiguo
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (01) : 107 - 117
  • [25] REPORTING FREQUENCY OF QT-INTERVAL ABNORMALITIES IN THE FDA ADVERSE EVENT REPORTING SYSTEM (FDA_AERS)
    Raschi, E.
    Poluzzi, E.
    Koci, A.
    De Ponti, F.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 84 - 84
  • [26] Adverse event monitoring and multivitamin-multimineral dietary supplements
    Woo, Jason J. Y.
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2007, 85 (01): : 323S - 324S
  • [27] Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
    Wen, Ming-Tao
    Li, Jia-Cheng
    Lu, Bo-Wen
    Shao, Hua-Rong
    Ling, Pei-Xue
    Liu, Fei
    Li, Gang
    Luo, Di
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [28] Signal detection of adverse reactions for bendamustine based on FDA adverse event reporting system
    Huang, Qing
    Wu, Yuanbin
    Li, Huimin
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [29] Adverse drug reactions in neonates: a brief analysis of the FDA adverse event reporting system
    Byskov, Pernille Kahler
    Baden, Christoffer Storm
    Andersen, Jon Traerup
    Jimenez-Solem, Espen
    Olsen, Ramus Huan
    Gade, Christina
    Lausten-Thomsen, Ulrik
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [30] An Algorithm to Identify Generic Drugs in the FDA Adverse Event Reporting System
    Iyer, Geetha
    Marimuthu, Sathiya Priya
    Segal, Jodi B.
    Singh, Sonal
    DRUG SAFETY, 2017, 40 (09) : 799 - 808